REGENXBIO’s Senior Director and Clinical Development Lead, Dr. Jahannaz Dastgir and Dr. Veerapandiyan from Arkansas Children’s Hospital share updates about RGX-202, an investigational gene therapy for the treatment of Duchenne muscular dystrophy (Duchenne) and trials: the AFFINITY DUCHENNE™ Phase I/II trial of RGX-202 and AFFINITY BEYOND™, an antibody assessment study in boys with Duchenne.
Recorded Wednesday, February 1st, 2023.
Aravindhan Veerapandiyan, MD
Aravindhan Veerapandiyan, MD (Dr. Panda) is a Child Neurologist and Assistant Professor with specialized interest and training in neuromuscular disorders in children. He is the Director of the Comprehensive Neuromuscular Program and Co-Director of the Muscular Dystrophy Association Care Center at ACH. He brings in training and expertise to perform electromyography and nerve conduction studies in children. Dr. Panda also has a particular interest in evaluating and treating children with headache disorders. He is the Medical Director of the Headache Clinic at ACH.
Jahannaz Dastgir, DO
Jahannaz Dastgir, DO is a pediatric neuromuscular specialist and the clinical development lead of the RGX-202 program at Regenxbio. This program focuses on AAV8 gene therapy for Duchenne Muscular Dystrophy.